Caspase 3/7 reagent (1:2000) is prepared and added to wells at 50 μL per well, together with 50 μL test substances. Anti-CD3, (final concentration 0.1 μg/mL), anti-CD28 (final concentration 0.5 μg/mL) and rhIL-2 (final concentration 10 ng/mL) are prepared in complete media and added in a final volume of 50 μL per well. Untouched PBMCs are prepared from cryopreserved stock and added to wells at 1×104 cells per well in a volume of 50 μL per well, such that the final well volume is 200 μL. Cells are incubated/monitored in the Incucyte Zoom® for a period of seven days.

[0949] Wells are imaged at 3-hour intervals in phase, green and red channels. Automated image analysis enables selective quantitation of SK-OV-3 nuclei (Red) per well, apoptotic SK-OV-3 nuclei (Green/Red colocalised) to enable the effect of test substance on apoptosis to be determined and quantified graphically over time.

1-54. (canceled)

55. A compound of Formula (I):



I

or a pharmaceutically acceptable salt, or a solvate, or a solvate of the salt thereof, wherein:

m is 0 or 1;

n is 0, 1 or 2;

X is —NR^8;

R^1 is H, C_{1-6}alkyl or a 6-10 membered aryl;

R^2 is a 5-6-membered heteroaryl, a fused 9-10 membered bicyclic heteroaryl, a 6-10 membered aryl, a 5-6 membered monocyclic heterocycloalkyl or a 5-11 membered spiroheteroalkyl or a fused 8-10 membered partially unsaturated bicyclic heterocyclyl; each of which may independently be optionally substituted by one or more groups independently selected from C_{1-6}alkyl, halogen, haloC_{1-6}alkyl, —OC_{1-6}alkyl, —CN, —C(═O)C_{1-6}alkyl, —C(═O)OC_{1-6}alkyl, —SO_2—C_{1-6}alkyl, —C(═O)NH_2, haloC_{1-6}alkyloxy or phenyl;

R^3 is H or C_{1-6}alkyl; or a 3-10 membered cycloalkyl, a 6-10 membered aryl, a 5-6 membered heteroaryl, a fused 9-10 membered bicyclic heteroaryl, a 4-6 membered monocyclic heterocycloalkyl, a —C_{1-6}alkyl-heteroaryl or a 5-11 membered spiroheteroalkyl; each of which may independently be optionally substituted by one or more groups independently selected from —C_{1-6}alkyl, —OC_{1-6}alkyl, halogen, —CN or —C(═O)OC_{1-6}alkyl;

A^1 is —N— or —CR^6—;

A^2 is —N— or —CR^5—;

A^3 is —N— or —CR^7—;

A^4 is —N—, —O—, —S—, —CH═N— or —CH═CR^4—;

R^4, R^5, R^6 and R^7, which may be the same or different, are each selected from —H, —OH, —C_{1-6}alkyl, halogen, haloC_{1-6}alkyl, —CN, —C_{1-6}alkyl-CN, —OC_{1-6}alkyl, —C_{2-6}alkynyl, —C_{2-6}alkynyl-C_{1-6}alkyl, —C_{2-6}alkynyl-aryl, —C_{2-6}alkynyl-C_{1-6}alkyl-aryl, —C_{2-6}alkynyl-C_{3-6}cycloalkyl, —C_{2-6}alkynyl-C_{1-6}alkyl-$NR^{11}R^{12}$, —C_{2-6}alkynyl-C_{1-6}alkyl-OR^{13}, —C(═O)C_{1-6}alkyl, —C(═O)NH_2, a 3-10 membered cycloalkyl, a 5-11 membered spiroalkyl, a 4-6 membered monocyclic heterocycloalkyl, a 6-10 membered aryl, a 5-6 membered heteroaryl, a 5-6 membered heteroC_{3-6}cycloalkyl, a fused 9-10 membered bicyclic heteroaryl, each of which may independently be optionally substituted by one or more groups independently selected from —C_{1-6}alkyl, C_{1-6}alkyl-NR^9R^{10}, —C_{1-6}alkyl-OH, —C(═O)OC_{1-6}alkyl or oxopyrrolidine;

or R^5 and R^7 together form a ring —CH═CH—CH═CH—, —OCH_2O— or —$CH_2CH_2CH_2$—;

or the moiety



may be fused with oxopyrrolidine; and

R^8, R^9, R^{10}, R^{11}, R^{12}, and R^{13}, which may be the same or different, are each selected from H or C_{1-6}alkyl;

provided that the compound of formula I is not 1-(4-chlorobenzyl)-1-cyclopentyl-3-phenylurea;

N-(3,5-dimethylphenyl)-3-ethyl-2-methyl-7-phenyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-6-carboxamide; [194]

1-cyclopentyl-3-phenyl-1-(2-thienylmethyl)urea; [195]

1-(4-chlorophenyl)-3-phenyl-1-(2-thienylmethyl)urea; [196]

1-[1-(4-fluorophenyl)ethyl]-3-phenyl-urea; [197]

1-(4-chlorophenyl)-3-[1-(5-chloro-2-thienyl)ethyl]urea; [199]

3-(3,4-dichlorophenyl)-1-methyl-1-(2-thienylmethyl) urea; [200]

1-[(5-methyl-2-phenyl-oxazol-4-yl)methyl]-3-phenyl-urea; [203] and

1-(3-chlorophenyl)-3-[(3-chloro-2-thienyl)methyl]urea; [204].

56-57. (canceled)

58. The compound according to claim **55**, wherein m is 1.

59. The compound according to claim **55**, wherein n is 0.

60. The compound according to claim **55**, wherein n is 2.

61. The compound according to claim **55**, wherein R^1 is H.

62. The compound according to claim **55**, wherein X is —NH—.

63. The compound according to claim **55**, wherein R^2 is a 5-6-membered heteroaryl or a fused 9-10 membered bicyclic heteroaryl.

64-66. (canceled)

67. The compound according to claim **55**, wherein R^3 is a 5-6-membered heteroaryl.

68. (canceled)

69. The compound according to claim **55**, wherein R^3 is a 4-6 membered monocyclic heterocycloalkyl.

70. (canceled)